Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001513162-20-000172
Filing Date
2020-08-17
Accepted
2020-08-17 16:27:50
Documents
1
Period of Report
2020-08-13

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 3966
  Complete submission text file 0001513162-20-000172.txt   5504
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Issuer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
SIC: 2834 Pharmaceutical Preparations

Mailing Address 3150 ALMADEN EXPRESSWAY SUITE 250 SAN JOSE CA 95118
Business Address
Gottschalk Emily (Reporting) CIK: 0001791108 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37492 | Film No.: 201110489